Endocyte, Inc. (ECYT) Hit 52-Week High at $12.56 on May, 16

May 16, 2018 - By Megan Stone

Big Money Sentiment increased to 1.36 in Q4 2017. It has change of 1.04, from 2017Q3’s 0.32. The ratio improved due to Endocyte, Inc. positioning: 11 sold and 14 reduced. 19 funds amassed positions and 15 increased positions. Investors holded 8.27 million in 2017Q3 but now own 19.91 million shares or 140.76% more.
Vanguard reported 1.63 million shs stake. Millennium Management Ltd Com stated it has 324,026 shs or 0% of all its holdings. Pinnacle Associates Ltd reported 0% stake. The California-based Schwab Charles Invest Mgmt has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). 3.44M were reported by Partner Fund Management Limited Partnership. Fmr Limited Liability Co has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Group Inc One Trading Lp reported 13,578 shs. Royal National Bank Of Canada reported 12,882 shs or 0% of all its holdings. First Financial In reported 0% stake. Wells Fargo Comm Mn reported 1,400 shs. Blackrock holds 1.14M shs or 0% of its capital. 1St Source Bank, Indiana-based fund reported 32,942 shs. Rmb Cap Ltd Llc owns 0.03% invested in Endocyte, Inc. (NASDAQ:ECYT) for 264,885 shs. Ameriprise Fincl, Minnesota-based fund reported 17,428 shs. Manufacturers Life Insurance The reported 1,801 shs or 0% of all its holdings.

Endocyte, Inc. registered $45,677 net activity with 0 insider buys and 1 insider sale since March 9, 2018.

Today 1-year high was reached by Endocyte, Inc. (NASDAQ:ECYT) with $13.44 target or 7.00 % above today’s $12.56 price per share. It was announced on May, 16 by Barchart.com. The company has $866.25M MC. $60.64M more could be NASDAQ:ECYT valuation at $13.44 share price.

The stock increased 3.72% or $0.45 during the last trading session, touching $12.56.Endocyte, Inc. has volume of 2.13 million shares. Since May 16, 2017 ECYT has risen 296.90% and is uptrending. ECYT outperformed by 285.35% the S&P 500.

Endocyte, Inc. (NASDAQ:ECYT)’s earnings report is anticipated on August, 14., according to Zacks. Last year’s earnings per share was $-0.28, while now analysts expect change of 32.14 % up from current $-0.19 earnings per share. Last quarter $-0.16 earnings per share was reported. Analysts predicts 18.75 % negative EPS growth this quarter.

Endocyte, Inc. (NASDAQ:ECYT) Ratings Coverage

A total of 3 analysts rate Endocyte (NASDAQ:ECYT) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. The firm has $20 highest and $17 lowest target. The avg target $18.50 is 47.29% above the last ($12.56) price. (NASDAQ:ECYT) has 3 ratings reports on May 16, 2018 according to StockzIntelligence. On Tuesday, February 27 the firm has “Outperform” rating by Cowen & Co given.

A couple more Endocyte, Inc. (NASDAQ:ECYT) news were posted by: Seekingalpha.com which released on May 09, 2018 “Endocyte’s (ECYT) CEO Mike Sherman on Q1 2018 Results – Earnings Call Transcript”, also Nasdaq.com on April 26, 2018 posted “New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals …”, the next Globenewswire.com is “Endocyte Announces First Quarter 2018 Earnings Call” on May 02, 2018. Globenewswire.com has article titled “Endocyte Provides First Quarter 2018 Financial Results and Operational Update”.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.The firm is worth $866.25 million. The firm uses its technology to create novel small molecule drug conjugates and companion imaging agents.Last it reported negative earnings. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

Endocyte, Inc. (NASDAQ:ECYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: